title: Cholesterol depletion of human immunodeficiency virus type 1 and simian immunodeficiency virus with beta-cyclodextrin inactivates and permeabilizes the virions: evidence for virion-associated lipid rafts.
abstract: Recent evidence suggests that human immunodeficiency virus type 1 (HIV-1) particles assemble and bud selectively through areas in the plasma membrane of cells that are highly enriched with glycosylphosphatidylinositol-anchored proteins and cholesterol, called lipid rafts. Since cholesterol is required to maintain lipid raft structure and function, we proposed that virion-associated cholesterol removal with the compound 2-hydroxy-propyl-beta-cyclodextrin (beta-CD) might be disruptive to HIV-1 and simian immunodeficiency virus (SIV). We examined the effect of beta-CD on the structure and infectivity of cell-free virions. We found that beta-CD inactivated HIV-1 and SIV in a dose-dependent manner and permeabilized the viral membranes, resulting in the loss of mature Gag proteins (capsid, matrix, nucleocapsid, p1, and p6) without loss of the envelope glycoproteins. SIV also lost reverse transcriptase (RT), integrase (IN), and viral RNA. IN appeared to be only slightly diminished in HIV-1, and viral RNA, RT, matrix, and nucleocapsid proteins were retained in HIV-1 but to a much lesser degree. Host proteins located internally in the virus (actin, moesin, and ezrin) and membrane-associated host proteins (major histocompatibility complex classes I and II) remained associated with the treated virions. Electron microscopy revealed that under conditions that permeabilized the viruses, holes were present in the viral membranes and the viral core structure was perturbed. These data provide evidence that an intact viral membrane is required to maintain mature virion core integrity. Since the viruses were not fixed before beta-CD treatment and intact virion particles were recovered, the data suggest that virions may possess a protein scaffold that can maintain overall structure despite disruptions in membrane integrity.
authors.affiliation: The Leukocyte Immunochemistry Laboratory, Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
authors.forename: David R M
authors.initials: DR
authors.lastname: Graham
authors.forename: Elena
authors.initials: E
authors.lastname: Chertova
authors.forename: Joanne M
authors.initials: JM
authors.lastname: Hilburn
authors.forename: Larry O
authors.initials: LO
authors.lastname: Arthur
authors.forename: James E K
authors.initials: JE
authors.lastname: Hildreth
mesh_terms: D000073738:2-Hydroxypropyl-beta-cyclodextrin; D036022:Capsid Proteins / Q000378:metabolism; D002462:Cell Membrane / Q000737:chemistry / Q000648:ultrastructure; D002463:Cell Membrane Permeability; D002784:Cholesterol / Q000378:metabolism*; D003505:Cyclodextrins / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D021962:Membrane Microdomains / Q000737:chemistry* / Q000648:ultrastructure; D008854:Microscopy, Electron; D015302:Simian Immunodeficiency Virus / Q000187:drug effects / Q000502:physiology*; D014407:Tumor Cells, Cultured; D014771:Virion / Q000737:chemistry* / Q000378:metabolism / Q000648:ultrastructure; D038301:Virus Inactivation; D047392:beta-Cyclodextrins
chemical_list: D036022:Capsid Proteins; D003505:Cyclodextrins; D047392:beta-Cyclodextrins; D000073738:2-Hydroxypropyl-beta-cyclodextrin; D002784:Cholesterol